Compound preparation for treating systemic lupus erythematosus

A compound preparation, a technology for lupus erythematosus, applied in the field of medicine, can solve problems such as affecting the quality of life and prognosis of patients, inducing infection, etc., and achieve the effects of enhancing biological effects, reducing incidence, and enhancing biological effects.

Inactive Publication Date: 2010-11-03
中国人民解放军济南军区第四〇一医院
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, long-term or large-scale use of glucocorticoids can lead to various side effects, such as osteoporosis, vertebral compression fractures, diabetes, hypertension, induced infection, gastrointestinal bleeding, etc. These problems seriously affect the quality of life and prognosis of patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound preparation for treating systemic lupus erythematosus
  • Compound preparation for treating systemic lupus erythematosus
  • Compound preparation for treating systemic lupus erythematosus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0012] Scheme 1 of the present invention (compound preparation A group): ginsenoside 400mg, prednisone 10mg,

[0013] Scheme 2 of the present invention (compound preparation B group): ginsenoside 400mg, methylprednisone 8mg;

[0014] It has been confirmed by clinical trials that the compound preparation can reduce the dosage of hormones to achieve the same therapeutic effect.

[0015] A randomized double-blind control design was adopted, and 90 patients with systemic lupus erythematosus who were admitted to the rheumatology department in outpatient clinics or wards were collected according to the inclusion and exclusion criteria. Randomly divided into three groups:

[0016] Prednisone routine treatment group, given prednisone 15mg orally, once a day;

[0017] Compound preparation group A was given a compound preparation containing 400 mg of ginsenoside and 10 mg of prednisone orally, once a day;

[0018] The compound preparation group B was given a compound preparation cont...

Embodiment 2

[0038] Scheme 3 of the present invention (compound preparation C group): ginsenoside 400mg and prednisone 20mg,

[0039] Scheme 4 of the present invention (compound preparation D group): ginsenoside 400mg and methylprednisone 16mg;

[0040] It is confirmed by clinical trials that the compound preparation can improve the curative effect of systemic lupus erythematosus.

[0041] A randomized double-blind control design was adopted, and 90 patients with systemic lupus erythematosus who were admitted to the rheumatology and immunology department and hospitalized in the ward were collected according to the inclusion and exclusion criteria. They were randomly divided into three groups: prednisone routine treatment group, oral prednisone 20mg once a day; compound preparation C group, compound preparation containing ginsenoside 400mg and prednisone 20mg orally once a day; compound preparation D Group, given the compound preparation containing ginsenoside 400mg and methylprednisolone ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a compound preparation for treating systemic lupus erythematosus. A grain of capsule of the compound preparation is prepared by combining 400 milligrams of ginsenoside and 10 to 20 milligrams of prednisone or 8 to 16 milligrams of meprednisone. The compound preparation not only enhances the biological effect of hormones, but also reduces the side effect of the hormones, so that the progress of the state of illness can be controlled more effectively. The compound preparation utilizes the effects of stress resistance, inflammatory resistance and the like of the ginsenoside used as main active ingredients of panax ginseng fully, has the two-way adjusting effect on the immunologic function and particularly has the synergistic effect with the prednisone, and is widely suitable for the treatment of autoimmune diseases.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a compound preparation for treating systemic lupus erythematosus, which consists of ginsenosides (GS) and prednisone or ginsenoside and methylprednisone in a certain proportion to form a compound preparation for more Effectively treat systemic lupus erythematosus (Systemic Lupus Erythematosus, SLE). Background technique [0002] Systemic lupus erythematosus is an autoimmune disease involving multiple systems and organs, and its pathogenesis may be related to genetic susceptibility, sex hormones, environmental factors, and immune dysfunction. The prevalence of this disease in women of childbearing age in my country can be as high as 113 cases / 100,000, and it has become an independent risk factor for early atherosclerosis and death in premenopausal women. The course of the disease is long, protracted and difficult to heal, and patients often need to take medicine for life. So fa...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/258A61K9/48A61P37/02A61P19/04A61K31/573
Inventor 封颖璐凌昌全
Owner 中国人民解放军济南军区第四〇一医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap